drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01041 | DB02546 | 770 | 137 | [
"DDInter1789",
"DDInter1947"
] | Thalidomide | Vorinostat | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Major | 2 | [
[
[
770,
25,
137
]
],
[
[
770,
24,
94
],
[
94,
1,
137
]
],
[
[
770,
5,
11555
],
[
11555,
44,
137
]
],
[
[
770,
7,
7669
],
[
7669,
46... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorinostat"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
],
[
"Phenace... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Vorinostat (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vorinostat (Compound)
Thalidomide (Compound) upregu... |
DB00712 | DB01254 | 1,274 | 1,213 | [
"DDInter763",
"DDInter484"
] | Flurbiprofen | Dasatinib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1274,
37,
1213
]
],
[
[
1274,
7,
6855
],
[
6855,
46,
1213
]
],
[
[
1274,
18,
3439
],
[
3439,
46,
1213
]
],
[
[
1274,
21,
28882
],
[
28... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) upregulates {v} (Gene)",
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and
Flurbiprofen (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Dasatinib (Compound)
Flurbiprofen (Compound) downregulates GRN (Gene) and GRN (Gene) is upregulated by Dasatinib (Compound)
F... |
DB00436 | DB00736 | 323 | 660 | [
"DDInter179",
"DDInter676"
] | Bendroflumethiazide | Esomeprazole | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Moderate | 1 | [
[
[
323,
24,
660
]
],
[
[
323,
24,
1215
],
[
1215,
40,
660
]
],
[
[
323,
63,
837
],
[
837,
1,
660
]
],
[
[
323,
21,
28785
],
[
28785,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansopr... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) rese... |
DB00682 | DB01404 | 126 | 757 | [
"DDInter1951",
"DDInter820"
] | Warfarin | Ginseng | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
126,
24,
757
]
],
[
[
126,
63,
245
],
[
245,
24,
757
]
],
[
[
126,
64,
25
],
[
25,
24,
757
]
],
[
[
126,
24,
578
],
[
578,
63,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"G... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Warfarin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a... |
DB00460 | DB00530 | 612 | 1,195 | [
"DDInter1929",
"DDInter667"
] | Verteporfin | Erlotinib | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Moderate | 1 | [
[
[
612,
24,
1195
]
],
[
[
612,
24,
1069
],
[
1069,
1,
1195
]
],
[
[
612,
63,
883
],
[
883,
40,
1195
]
],
[
[
612,
21,
28792
],
[
28792,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib (Compound) resembles Erlotinib (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
Ve... |
DB01128 | DB01165 | 918 | 1,539 | [
"DDInter204",
"DDInter1325"
] | Bicalutamide | Ofloxacin | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
918,
24,
1539
]
],
[
[
918,
64,
1176
],
[
1176,
1,
1539
]
],
[
[
918,
25,
945
],
[
945,
40,
1539
]
],
[
[
918,
63,
956
],
[
956,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxif... | Bicalutamide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Bicalutamide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Bicalutamide may cau... |
DB00215 | DB09241 | 1,230 | 1,629 | [
"DDInter388",
"DDInter1186"
] | Citalopram | Methylene blue | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
1230,
25,
1629
]
],
[
[
1230,
25,
1148
],
[
1148,
24,
1629
]
],
[
[
1230,
24,
659
],
[
659,
24,
1629
]
],
[
[
1230,
64,
73
],
[
73,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
... | Citalopram may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol ma... |
DB01165 | DB01246 | 1,539 | 820 | [
"DDInter1325",
"DDInter45"
] | Ofloxacin | Alimemazine | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1539,
24,
820
]
],
[
[
1539,
63,
401
],
[
401,
24,
820
]
],
[
[
1539,
21,
29339
],
[
29339,
60,
820
]
],
[
[
1539,
24,
286
],
[
286,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Ofloxacin (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is... |
DB06414 | DB08871 | 655 | 36 | [
"DDInter703",
"DDInter666"
] | Etravirine | Eribulin | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
655,
24,
36
]
],
[
[
655,
63,
1488
],
[
1488,
24,
36
]
],
[
[
655,
62,
168
],
[
168,
24,
36
]
],
[
[
655,
24,
384
],
[
384,
63,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezom... |
DB01001 | DB09078 | 688 | 1,228 | [
"DDInter1632",
"DDInter1036"
] | Salbutamol | Lenvatinib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
688,
24,
1228
]
],
[
[
688,
62,
112
],
[
112,
23,
1228
]
],
[
[
688,
23,
1247
],
[
1247,
23,
1228
]
],
[
[
688,
63,
1100
],
[
1100,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and ... |
DB01253 | DB14723 | 628 | 159 | [
"DDInter664",
"DDInter1026"
] | Ergometrine | Larotrectinib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
628,
24,
159
]
],
[
[
628,
63,
597
],
[
597,
24,
159
]
],
[
[
628,
24,
951
],
[
951,
24,
159
]
],
[
[
628,
1,
1131
],
[
1131,
24... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Palboc... |
DB00390 | DB08899 | 1,252 | 129 | [
"DDInter554",
"DDInter649"
] | Digoxin | Enzalutamide | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1252,
24,
129
]
],
[
[
1252,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1252,
18,
5562
],
[
5562,
46,
129
]
],
[
[
1252,
21,
28921
],
[
28921... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Digoxin (Compound) downregulates LOXL1 (Gene) and LOXL1 (Gene) is upregulated by Enzalutamide (Compound)
Digoxin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Digoxin... |
DB09073 | DB12887 | 951 | 1,598 | [
"DDInter1379",
"DDInter1750"
] | Palbociclib | Tazemetostat | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
951,
24,
1598
]
],
[
[
951,
24,
985
],
[
985,
24,
1598
]
],
[
[
951,
63,
134
],
[
134,
24,
1598
]
],
[
[
951,
24,
982
],
[
982,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and... |
DB00539 | DB12245 | 11 | 823 | [
"DDInter1837",
"DDInter1863"
] | Toremifene | Triclabendazole | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
11,
25,
823
]
],
[
[
11,
23,
1247
],
[
1247,
23,
823
]
],
[
[
11,
25,
1612
],
[
1612,
24,
823
]
],
[
[
11,
64,
1010
],
[
1010,
2... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Toremifene may lead to a major life threatening interaction when taken with Fostemsavir and Fostems... |
DB00241 | DB04845 | 288 | 309 | [
"DDInter257",
"DDInter1001"
] | Butalbital | Ixabepilone | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
288,
24,
309
]
],
[
[
288,
24,
1419
],
[
1419,
24,
309
]
],
[
[
288,
24,
1593
],
[
1593,
63,
309
]
],
[
[
288,
40,
1023
],
[
1023,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotini... |
DB01619 | DB05381 | 830 | 172 | [
"DDInter1441",
"DDInter863"
] | Phenindamine | Histamine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
830,
24,
172
]
],
[
[
830,
63,
1264
],
[
1264,
24,
172
]
],
[
[
830,
24,
337
],
[
337,
63,
172
]
],
[
[
830,
40,
104
],
[
104,
2... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phe... |
DB00981 | DB01173 | 1,528 | 358 | [
"DDInter1462",
"DDInter1349"
] | Physostigmine | Orphenadrine | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1528,
24,
358
]
],
[
[
1528,
24,
211
],
[
211,
1,
358
]
],
[
[
1528,
24,
272
],
[
272,
24,
358
]
],
[
[
1528,
24,
820
],
[
820,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate ... |
DB08903 | DB11718 | 996 | 927 | [
"DDInter170",
"DDInter640"
] | Bedaquiline | Encorafenib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
996,
25,
927
]
],
[
[
996,
62,
112
],
[
112,
23,
927
]
],
[
[
996,
24,
720
],
[
720,
24,
927
]
],
[
[
996,
63,
372
],
[
372,
24,... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Bedaquiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00022 | DB00995 | 268 | 1,112 | [
"DDInter1408",
"DDInter139"
] | Peginterferon alfa-2b | Auranofin | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
268,
24,
1112
]
],
[
[
268,
24,
36
],
[
36,
63,
1112
]
],
[
[
268,
24,
134
],
[
134,
24,
1112
]
],
[
[
268,
63,
491
],
[
491,
24... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribul... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Auranofin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Vino... |
DB00557 | DB08899 | 252 | 129 | [
"DDInter895",
"DDInter649"
] | Hydroxyzine | Enzalutamide | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
252,
24,
129
]
],
[
[
252,
24,
918
],
[
918,
1,
129
]
],
[
[
252,
6,
12523
],
[
12523,
45,
129
]
],
[
[
252,
21,
28751
],
[
28751,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Hydroxyzine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Hydroxyzine (Compound) causes Convulsion (Side Effect) a... |
DB00497 | DB06274 | 828 | 574 | [
"DDInter1366",
"DDInter59"
] | Oxycodone | Alvimopan | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period. | Major | 2 | [
[
[
828,
25,
574
]
],
[
[
828,
6,
6291
],
[
6291,
45,
574
]
],
[
[
828,
21,
28759
],
[
28759,
60,
574
]
],
[
[
828,
24,
214
],
[
214,
... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alvimopan"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"OPRD1"
],
[
"OPRD1",
"{u} (Gene) is bound by {v} (Compound)",
"Alvimopan"
... | Oxycodone (Compound) binds OPRD1 (Gene) and OPRD1 (Gene) is bound by Alvimopan (Compound)
Oxycodone (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Alvimopan (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when tak... |
DB00207 | DB01611 | 1,570 | 1,487 | [
"DDInter157",
"DDInter893"
] | Azithromycin | Hydroxychloroquine | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1570,
25,
1487
]
],
[
[
1570,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1570,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1570,
24,
663
],
[
6... | [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Azithromycin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Com... |
DB00586 | DB00745 | 1,512 | 307 | [
"DDInter537",
"DDInter1236"
] | Diclofenac | Modafinil | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
1512,
23,
307
]
],
[
[
1512,
63,
1236
],
[
1236,
40,
307
]
],
[
[
1512,
1,
282
],
[
282,
40,
307
]
],
[
[
1512,
24,
998
],
[
998,
... | [
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Modafinil (Compound)
Diclofenac (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Modafinil (Compound)
Diclofenac may cause a moderate interaction th... |
DB00675 | DB08820 | 888 | 1,478 | [
"DDInter1744",
"DDInter997"
] | Tamoxifen | Ivacaftor | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
888,
24,
1478
]
],
[
[
888,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
888,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
888,
24,
307
],
[
307,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Tamoxifen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil ma... |
DB00427 | DB01200 | 1,233 | 469 | [
"DDInter1879",
"DDInter243"
] | Triprolidine | Bromocriptine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
1233,
24,
469
]
],
[
[
1233,
24,
401
],
[
401,
24,
469
]
],
[
[
1233,
63,
701
],
[
701,
24,
469
]
],
[
[
1233,
24,
407
],
[
407,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine... |
DB00207 | DB00836 | 1,570 | 543 | [
"DDInter157",
"DDInter1088"
] | Azithromycin | Loperamide | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1570,
24,
543
]
],
[
[
1570,
24,
888
],
[
888,
24,
543
]
],
[
[
1570,
6,
8374
],
[
8374,
45,
543
]
],
[
[
1570,
7,
9242
],
[
9242,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Azithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loperamide (Compound)
Azithromycin (Co... |
DB00331 | DB00562 | 1,645 | 1,014 | [
"DDInter1164",
"DDInter188"
] | Metformin | Benzthiazide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
1645,
24,
1014
]
],
[
[
1645,
24,
811
],
[
811,
40,
1014
]
],
[
[
1645,
24,
674
],
[
674,
1,
1014
]
],
[
[
1645,
24,
126
],
[
126,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Benzth... |
DB06403 | DB12130 | 1,204 | 1,017 | [
"DDInter62",
"DDInter1094"
] | Ambrisentan | Lorlatinib | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1204,
24,
1017
]
],
[
[
1204,
24,
1491
],
[
1491,
24,
1017
]
],
[
[
1204,
63,
549
],
[
549,
24,
1017
]
],
[
[
1204,
24,
971
],
[
971,
... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[... | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and... |
DB00845 | DB12332 | 1,490 | 1,619 | [
"DDInter406",
"DDInter1626"
] | Clofazimine | Rucaparib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1490,
24,
1619
]
],
[
[
1490,
23,
112
],
[
112,
23,
1619
]
],
[
[
1490,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1490,
63,
888
],
[
888,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid ... |
DB01030 | DB11986 | 869 | 484 | [
"DDInter1835",
"DDInter648"
] | Topotecan | Entrectinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
869,
24,
484
]
],
[
[
869,
24,
466
],
[
466,
62,
484
]
],
[
[
869,
23,
1539
],
[
1539,
24,
484
]
],
[
[
869,
63,
322
],
[
322,
2... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Topotecan may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxaci... |
DB06218 | DB12267 | 136 | 1,476 | [
"DDInter1014",
"DDInter233"
] | Lacosamide | Brigatinib | Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commissio... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
136,
24,
1476
]
],
[
[
136,
1,
168
],
[
168,
23,
1476
]
],
[
[
136,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
136,
63,
1010
],
[
1010,
... | [
[
[
"Lacosamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Lacosamide",
"{u} (Compound) resembles {v} (Compound)",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor i... | Lacosamide (Compound) resembles Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exa... |
DB01224 | DB06203 | 623 | 1,002 | [
"DDInter1553",
"DDInter51"
] | Quetiapine | Alogliptin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
623,
24,
1002
]
],
[
[
623,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
623,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
623,
21,
28873
],
[
2887... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Quetiapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Quetiapine (Compound) causes Pancreatitis (Side Effect) and Panc... |
DB00226 | DB01124 | 1,000 | 1,411 | [
"DDInter845",
"DDInter1828"
] | Guanadrel | Tolbutamide | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1000,
24,
1411
]
],
[
[
1000,
24,
959
],
[
959,
40,
1411
]
],
[
[
1000,
63,
245
],
[
245,
40,
1411
]
],
[
[
1000,
24,
1296
],
[
1296,
... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
... |
DB00683 | DB01233 | 1,382 | 1,311 | [
"DDInter1212",
"DDInter1197"
] | Midazolam | Metoclopramide | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1382,
24,
1311
]
],
[
[
1382,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1382,
24,
629
],
[
629,
24,
1311
]
],
[
[
1382,
24,
649
],
[
649... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Midazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ... | Midazolam (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Metoc... |
DB00467 | DB01168 | 1,467 | 1,053 | [
"DDInter644",
"DDInter1526"
] | Enoxacin | Procarbazine | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Minor | 0 | [
[
[
1467,
23,
1053
]
],
[
[
1467,
24,
848
],
[
848,
40,
1053
]
],
[
[
1467,
18,
4930
],
[
4930,
57,
1053
]
],
[
[
1467,
40,
246
],
[
246,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Enoxacin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound)
Enoxacin (Compound) resembles Gatifloxacin (Compound) and ... |
DB00741 | DB04868 | 167 | 478 | [
"DDInter885",
"DDInter1293"
] | Hydrocortisone | Nilotinib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
167,
24,
478
]
],
[
[
167,
6,
4973
],
[
4973,
45,
478
]
],
[
[
167,
7,
4759
],
[
4759,
46,
478
]
],
[
[
167,
6,
1899
],
[
1899,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compou... | Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Hydrocortisone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Nilotinib (Compound)
Hydrocortisone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Nilotinib (Compound)
Hydrocortis... |
DB00531 | DB05679 | 450 | 1,683 | [
"DDInter456",
"DDInter1907"
] | Cyclophosphamide | Ustekinumab | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
450,
24,
1683
]
],
[
[
450,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
450,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
450,
1,
1001
],
[
1001,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and... |
DB00074 | DB06688 | 1,309 | 1,430 | [
"DDInter166",
"DDInter1677"
] | Basiliximab | Sipuleucel-T | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1309,
24,
1430
]
],
[
[
1309,
25,
676
],
[
676,
63,
1430
]
],
[
[
1309,
24,
1531
],
[
1531,
24,
1430
]
],
[
[
1309,
24,
713
],
[
713,
... | [
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upad... | Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab ... |
DB08875 | DB08899 | 1,618 | 129 | [
"DDInter262",
"DDInter649"
] | Cabozantinib | Enzalutamide | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
1618,
25,
129
]
],
[
[
1618,
64,
918
],
[
918,
1,
129
]
],
[
[
1618,
62,
1247
],
[
1247,
23,
129
]
],
[
[
1618,
25,
230
],
[
230,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Cabozantinib may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can... |
DB00001 | DB06186 | 1,578 | 1,439 | [
"DDInter1037",
"DDInter969"
] | Lepirudin | Ipilimumab | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Major | 2 | [
[
[
1578,
25,
1439
]
],
[
[
1578,
25,
1468
],
[
1468,
63,
1439
]
],
[
[
1578,
25,
4
],
[
4,
24,
1439
]
],
[
[
1578,
25,
1409
],
[
1409,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may c... | Lepirudin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lepirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate... |
DB00501 | DB06589 | 752 | 1,250 | [
"DDInter380",
"DDInter1400"
] | Cimetidine | Pazopanib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
752,
25,
1250
]
],
[
[
752,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
752,
18,
8954
],
[
8954,
57,
1250
]
],
[
[
752,
21,
28658
],
[
28658,... | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopani... | Cimetidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Cimetidine (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) is downregulated by Pazopanib (Compound)
Cimetidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Cimetid... |
DB09083 | DB11363 | 880 | 1,276 | [
"DDInter996",
"DDInter39"
] | Ivabradine | Alectinib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
880,
24,
1276
]
],
[
[
880,
63,
61
],
[
61,
24,
1276
]
],
[
[
880,
64,
1424
],
[
1424,
24,
1276
]
],
[
[
880,
24,
1476
],
[
1476,
... | [
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
... | Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Ivabradine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a mod... |
DB00334 | DB09472 | 867 | 1,383 | [
"DDInter1326",
"DDInter1693"
] | Olanzapine | Sodium sulfate | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
867,
24,
1383
]
],
[
[
867,
24,
609
],
[
609,
24,
1383
]
],
[
[
867,
25,
1311
],
[
1311,
24,
1383
]
],
[
[
867,
63,
521
],
[
521,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Olanzapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoc... |
DB00072 | DB10429 | 550 | 200 | [
"DDInter1846",
"DDInter282"
] | Trastuzumab | Candida albicans | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
550,
24,
200
]
],
[
[
550,
24,
1683
],
[
1683,
24,
200
]
],
[
[
550,
25,
976
],
[
976,
24,
200
]
],
[
[
550,
24,
738
],
[
738,
6... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Trastuzumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitini... |
DB00188 | DB01030 | 168 | 869 | [
"DDInter222",
"DDInter1835"
] | Bortezomib | Topotecan | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
168,
24,
869
]
],
[
[
168,
6,
8374
],
[
8374,
45,
869
]
],
[
[
168,
7,
1933
],
[
1933,
46,
869
]
],
[
[
168,
18,
13115
],
[
13115,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topotecan (Compound)
Bortezomib (Compound) upregulates TNFAIP3 (Gene) and TNFAIP3 (Gene) is upregulated by Topotecan (Compound)
Bortezomib (Compound) downregulates C19orf24 (Gene) and C19orf24 (Gene) is upregulated by Topotecan (Compound)
Bortezomi... |
DB00264 | DB00741 | 88 | 167 | [
"DDInter1200",
"DDInter885"
] | Metoprolol | Hydrocortisone | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
88,
24,
167
]
],
[
[
88,
24,
1220
],
[
1220,
40,
167
]
],
[
[
88,
24,
870
],
[
870,
1,
167
]
],
[
[
88,
6,
4973
],
[
4973,
45,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hy... |
DB09036 | DB14409 | 812 | 1,129 | [
"DDInter1668",
"DDInter867"
] | Siltuximab | Human adenovirus e serotype 4 strain cl-68578 antigen | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
812,
24,
1129
]
],
[
[
812,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
812,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
812,
24,
1456
],
[
1456,
... | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Siltuximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Siltuximab may cause a moderate interaction that could exacerbate diseases when take... |
DB09280 | DB15035 | 1,604 | 503 | [
"DDInter1101",
"DDInter1959"
] | Lumacaftor | Zanubrutinib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
1604,
25,
503
]
],
[
[
1604,
25,
982
],
[
982,
24,
503
]
],
[
[
1604,
64,
868
],
[
868,
24,
503
]
],
[
[
1604,
63,
522
],
[
522,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u}... | Lumacaftor may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Lumacaftor may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate ... |
DB00938 | DB11952 | 455 | 800 | [
"DDInter1635",
"DDInter612"
] | Salmeterol | Duvelisib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
455,
24,
800
]
],
[
[
455,
24,
222
],
[
222,
23,
800
]
],
[
[
455,
63,
1324
],
[
1324,
24,
800
]
],
[
[
455,
24,
1213
],
[
1213,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Trogl... |
DB00069 | DB01235 | 367 | 1,191 | [
"DDInter946",
"DDInter1054"
] | Interferon alfacon-1 | Levodopa | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
367,
24,
1191
]
],
[
[
367,
24,
63
],
[
63,
24,
1191
]
],
[
[
367,
24,
148
],
[
148,
63,
1191
]
],
[
[
367,
25,
1377
],
[
1377,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposid... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Sec... |
DB01015 | DB09564 | 1,247 | 1,296 | [
"DDInter1724",
"DDInter930"
] | Sulfamethoxazole | Insulin degludec | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1247,
24,
1296
]
],
[
[
1247,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1247,
23,
1151
],
[
1151,
24,
1296
]
],
[
[
1247,
62,
485
],
[
485... | [
[
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutami... | Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sun... |
DB00065 | DB01005 | 581 | 995 | [
"DDInter923",
"DDInter894"
] | Infliximab | Hydroxyurea | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Major | 2 | [
[
[
581,
25,
995
]
],
[
[
581,
25,
1238
],
[
1238,
24,
995
]
],
[
[
581,
25,
869
],
[
869,
63,
995
]
],
[
[
581,
64,
1648
],
[
1648,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u... | Infliximab may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Infliximab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate int... |
DB09039 | DB11967 | 1,670 | 710 | [
"DDInter629",
"DDInter210"
] | Eliglustat | Binimetinib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1670,
24,
710
]
],
[
[
1670,
64,
441
],
[
441,
24,
710
]
],
[
[
1670,
63,
1237
],
[
1237,
24,
710
]
],
[
[
1670,
25,
68
],
[
68,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavird... | Eliglustat may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may... |
DB00959 | DB06643 | 1,486 | 1,136 | [
"DDInter1191",
"DDInter500"
] | Methylprednisolone | Denosumab | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1486,
24,
1136
]
],
[
[
1486,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
1486,
24,
1316
],
[
1316,
63,
1136
]
],
[
[
1486,
63,
1419
],
[
14... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Durvalum... |
DB00262 | DB00754 | 552 | 157 | [
"DDInter302",
"DDInter696"
] | Carmustine | Ethotoin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
552,
24,
157
]
],
[
[
552,
24,
697
],
[
697,
40,
157
]
],
[
[
552,
21,
28763
],
[
28763,
60,
157
]
],
[
[
552,
24,
663
],
[
663,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Ethotoin (Compound)
Carmustine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Ethotoin (Compound)
Carmustine may cause a moderate interact... |
DB01285 | DB14783 | 708 | 287 | [
"DDInter445",
"DDInter574"
] | Corticotropin | Diroximel fumarate | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
708,
24,
287
]
],
[
[
708,
63,
599
],
[
599,
24,
287
]
],
[
[
708,
24,
270
],
[
270,
24,
287
]
],
[
[
708,
25,
1510
],
[
1510,
2... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB00685 | DB01024 | 1,299 | 1,096 | [
"DDInter1887",
"DDInter1252"
] | Trovafloxacin | Mycophenolic acid | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1299,
24,
1096
]
],
[
[
1299,
21,
29687
],
[
29687,
60,
1096
]
],
[
[
1299,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
1299,
63,
965
],
[
9... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Fungal skin infection"
],
[
"Fungal skin infecti... | Trovafloxacin (Compound) causes Fungal skin infection (Side Effect) and Fungal skin infection (Side Effect) is caused by Mycophenolic acid (Compound)
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can lim... |
DB00694 | DB00738 | 51 | 485 | [
"DDInter485",
"DDInter1420"
] | Daunorubicin | Pentamidine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
51,
24,
485
]
],
[
[
51,
6,
7524
],
[
7524,
45,
485
]
],
[
[
51,
18,
5295
],
[
5295,
46,
485
]
],
[
[
51,
7,
7158
],
[
7158,
46,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compou... | Daunorubicin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Pentamidine (Compound)
Daunorubicin (Compound) downregulates CDK7 (Gene) and CDK7 (Gene) is upregulated by Pentamidine (Compound)
Daunorubicin (Compound) upregulates TIMP2 (Gene) and TIMP2 (Gene) is upregulated by Pentamidine (Compound)
Daunorubi... |
DB08869 | DB08882 | 162 | 1,281 | [
"DDInter1773",
"DDInter1070"
] | Tesamorelin | Linagliptin | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
162,
24,
1281
]
],
[
[
162,
63,
1002
],
[
1002,
1,
1281
]
],
[
[
162,
63,
1685
],
[
1685,
24,
1281
]
],
[
[
162,
24,
1296
],
[
1296,
... | [
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction t... |
DB01001 | DB14568 | 688 | 982 | [
"DDInter1632",
"DDInter1000"
] | Salbutamol | Ivosidenib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
688,
24,
982
]
],
[
[
688,
62,
112
],
[
112,
23,
982
]
],
[
[
688,
23,
1247
],
[
1247,
23,
982
]
],
[
[
688,
63,
543
],
[
543,
2... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and ... |
DB08904 | DB11793 | 375 | 738 | [
"DDInter342",
"DDInter1297"
] | Certolizumab pegol | Niraparib | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Major | 2 | [
[
[
375,
25,
738
]
],
[
[
375,
64,
1213
],
[
1213,
24,
738
]
],
[
[
375,
24,
496
],
[
496,
24,
738
]
],
[
[
375,
63,
759
],
[
759,
2... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",... | Certolizumab pegol may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and... |
DB00491 | DB06343 | 127 | 1,379 | [
"DDInter1217",
"DDInter1766"
] | Miglitol | Teprotumumab | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
127,
24,
1379
]
],
[
[
127,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
127,
24,
959
],
[
959,
24,
1379
]
],
[
[
127,
63,
1179
],
[
1179,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide a... |
DB00861 | DB01166 | 914 | 477 | [
"DDInter551",
"DDInter379"
] | Diflunisal | Cilostazol | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
914,
24,
477
]
],
[
[
914,
21,
29340
],
[
29340,
60,
477
]
],
[
[
914,
64,
126
],
[
126,
23,
477
]
],
[
[
914,
24,
936
],
[
936,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Diflunisal",
"{u} (Compound) causes {v} (Side Effect)",
"Stevens-Johnson syndrome"
],
[
"Stevens-Johnson syndrome",
... | Diflunisal (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Diflunisal may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken wit... |
DB00912 | DB01277 | 473 | 1,022 | [
"DDInter1581",
"DDInter1131"
] | Repaglinide | Mecasermin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human I... | Moderate | 1 | [
[
[
473,
24,
1022
]
],
[
[
473,
24,
824
],
[
824,
24,
1411
],
[
1411,
24,
1022
]
],
[
[
473,
5,
11640
],
[
11640,
44,
1411
],
[
1411,
24... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin
Rep... |
DB06702 | DB08820 | 573 | 1,478 | [
"DDInter731",
"DDInter997"
] | Fesoterodine | Ivacaftor | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
573,
24,
1478
]
],
[
[
573,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
573,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
573,
24,
1040
],
[
1040,... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Fesoterodine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fesoterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Fesoterodine (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib ... |
DB00880 | DB01069 | 359 | 401 | [
"DDInter360",
"DDInter1533"
] | Chlorothiazide | Promethazine | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
359,
24,
401
]
],
[
[
359,
24,
1264
],
[
1264,
63,
401
]
],
[
[
359,
24,
104
],
[
104,
24,
401
]
],
[
[
359,
21,
28709
],
[
28709,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and ... |
DB00026 | DB01182 | 1,184 | 371 | [
"DDInter94",
"DDInter1534"
] | Anakinra | Propafenone | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
1184,
24,
371
]
],
[
[
1184,
24,
704
],
[
704,
1,
371
]
],
[
[
1184,
24,
608
],
[
608,
23,
371
]
],
[
[
1184,
24,
126
],
[
126,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Propafenone (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinica... |
DB00685 | DB08870 | 1,299 | 850 | [
"DDInter1887",
"DDInter228"
] | Trovafloxacin | Brentuximab vedotin | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1299,
24,
850
]
],
[
[
1299,
23,
611
],
[
611,
24,
850
]
],
[
[
1299,
24,
267
],
[
267,
24,
850
]
],
[
[
1299,
62,
134
],
[
134,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacarbazine"
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Naltre... |
DB00209 | DB00543 | 352 | 87 | [
"DDInter1886",
"DDInter82"
] | Trospium | Amoxapine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
352,
24,
87
]
],
[
[
352,
24,
623
],
[
623,
40,
87
]
],
[
[
352,
24,
1408
],
[
1408,
1,
87
]
],
[
[
352,
6,
12523
],
[
12523,
45... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine (Compound) resembles Amoxapine (Compound)
Trospium (... |
DB01357 | DB08890 | 890 | 16 | [
"DDInter1160",
"DDInter1069"
] | Mestranol | Linaclotide | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Moderate | 1 | [
[
[
890,
24,
16
]
],
[
[
890,
1,
566
],
[
566,
24,
16
]
],
[
[
890,
63,
542
],
[
542,
24,
16
]
],
[
[
890,
1,
566
],
[
566,
40,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linaclotide"
]
],
[
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} may cause a ... | Mestranol (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide
Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interacti... |
DB00041 | DB09498 | 1,648 | 810 | [
"DDInter38",
"DDInter1715"
] | Aldesleukin | Strontium chloride Sr-89 | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
1648,
24,
810
]
],
[
[
1648,
24,
552
],
[
552,
24,
810
]
],
[
[
1648,
25,
589
],
[
589,
24,
810
]
],
[
[
1648,
24,
385
],
[
385,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Aldesleukin may lead to a major life threatening interaction when taken with Cisplatin and Cispla... |
DB00432 | DB11601 | 1,083 | 1,270 | [
"DDInter1868",
"DDInter1889"
] | Trifluridine | Tuberculin purified protein derivative | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1083,
24,
1270
]
],
[
[
1083,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1083,
75,
1064
],
[
1064,
24,
1270
]
],
[
[
1083,
63,
599
],
[
599... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lea... |
DB01005 | DB01181 | 995 | 1,532 | [
"DDInter894",
"DDInter906"
] | Hydroxyurea | Ifosfamide | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
995,
24,
1532
]
],
[
[
995,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
995,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
995,
62,
1299
],
[
129... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Hydroxyurea",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Hydroxyurea (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Hydroxyurea (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Hydroxyurea may cause a minor interaction that can limit clinical effects whe... |
DB00827 | DB08882 | 646 | 1,281 | [
"DDInter383",
"DDInter1070"
] | Cinoxacin | Linagliptin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
646,
24,
1281
]
],
[
[
646,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
646,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
646,
64,
251
],
[
251,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Cinoxacin (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Cinoxacin may lead to a major life threate... |
DB00818 | DB01064 | 898 | 1,148 | [
"DDInter1538",
"DDInter987"
] | Propofol | Isoprenaline | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
898,
24,
1148
]
],
[
[
898,
24,
480
],
[
480,
24,
1148
]
],
[
[
898,
6,
9842
],
[
9842,
45,
1148
]
],
[
[
898,
21,
28717
],
[
28717,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Propofol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Isoprenaline (Compound)
Propofol (Compound... |
DB00459 | DB12455 | 640 | 933 | [
"DDInter21",
"DDInter1336"
] | Acitretin | Omadacycline | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Major | 2 | [
[
[
640,
25,
933
]
],
[
[
640,
24,
92
],
[
92,
24,
933
]
],
[
[
640,
25,
1517
],
[
1517,
25,
933
]
],
[
[
640,
24,
92
],
[
92,
24,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omadacycline"
]
],
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
],
[
"Methoxsal... | Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may ... |
DB00550 | DB08886 | 99 | 637 | [
"DDInter1541",
"DDInter126"
] | Propylthiouracil | Asparaginase Erwinia chrysanthemi | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
99,
24,
637
]
],
[
[
99,
24,
850
],
[
850,
24,
637
]
],
[
[
99,
63,
482
],
[
482,
24,
637
]
],
[
[
99,
24,
1613
],
[
1613,
63,
... | [
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Propylthiouracil may cause a moderate interaction that could exac... |
DB00598 | DB01284 | 1,523 | 1,042 | [
"DDInter1013",
"DDInter1782"
] | Labetalol | Tetracosactide | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1523,
24,
1042
]
],
[
[
1523,
25,
455
],
[
455,
23,
1042
]
],
[
[
1523,
24,
1148
],
[
1148,
23,
1042
]
],
[
[
1523,
25,
659
],
[
659,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeter... | Labetalol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may ca... |
DB00586 | DB00903 | 1,512 | 1,680 | [
"DDInter537",
"DDInter686"
] | Diclofenac | Etacrynic acid | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
1512,
24,
1680
]
],
[
[
1512,
6,
10612
],
[
10612,
45,
1680
]
],
[
[
1512,
21,
29222
],
[
29222,
60,
1680
]
],
[
[
1512,
24,
1479
],
[
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compo... | Diclofenac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Etacrynic acid (Compound)
Diclofenac (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Etacrynic acid (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00736 | DB01112 | 660 | 665 | [
"DDInter676",
"DDInter335"
] | Esomeprazole | Cefuroxime | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Moderate | 1 | [
[
[
660,
24,
665
]
],
[
[
660,
24,
1462
],
[
1462,
1,
665
]
],
[
[
660,
21,
28784
],
[
28784,
60,
665
]
],
[
[
660,
24,
1448
],
[
1448,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
],
... | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefuroxime (Compound)
Esomeprazole (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Cefuroxime (Compound)
Esomeprazole may cause a m... |
DB05015 | DB10276 | 1,077 | 1,624 | [
"DDInter174",
"DDInter1623"
] | Belinostat | Rotavirus vaccine | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1077,
25,
1624
]
],
[
[
1077,
25,
375
],
[
375,
25,
1624
]
],
[
[
1077,
63,
58
],
[
58,
25,
1624
]
],
[
[
1077,
24,
270
],
[
270,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizum... | Belinostat may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may ... |
DB00366 | DB00470 | 1,594 | 530 | [
"DDInter600",
"DDInter601"
] | Doxylamine | Dronabinol | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
1594,
24,
530
]
],
[
[
1594,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1594,
21,
28708
],
[
28708,
60,
530
]
],
[
[
1594,
74,
701
],
[
701,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Doxylamine (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Dronabinol (Compound)
Doxylamine (Compound) resembles Clemastine (Compound... |
DB00401 | DB08904 | 84 | 375 | [
"DDInter1298",
"DDInter342"
] | Nisoldipine | Certolizumab pegol | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
84,
24,
375
]
],
[
[
84,
24,
1593
],
[
1593,
24,
375
]
],
[
[
84,
1,
409
],
[
409,
24,
375
]
],
[
[
84,
40,
1428
],
[
1428,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Nisoldipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction ... |
DB00434 | DB01168 | 13 | 1,053 | [
"DDInter459",
"DDInter1526"
] | Cyproheptadine | Procarbazine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
13,
24,
1053
]
],
[
[
13,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
13,
24,
9
],
[
9,
63,
1053
]
],
[
[
13,
24,
100
],
[
100,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect)... | Cyproheptadine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases w... |
DB00405 | DB01168 | 128 | 1,053 | [
"DDInter517",
"DDInter1526"
] | Dexbrompheniramine | Procarbazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
128,
24,
1053
]
],
[
[
128,
24,
9
],
[
9,
63,
1053
]
],
[
[
128,
24,
100
],
[
100,
24,
1053
]
],
[
[
128,
63,
701
],
[
701,
24,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrim... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when ... |
DB00888 | DB06643 | 1,001 | 1,136 | [
"DDInter1133",
"DDInter500"
] | Mechlorethamine | Denosumab | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1001,
24,
1136
]
],
[
[
1001,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1001,
24,
1532
],
[
1532,
24,
1136
]
],
[
[
1001,
25,
1377
],
[
13... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide... |
DB00734 | DB00902 | 1,664 | 104 | [
"DDInter1605",
"DDInter1168"
] | Risperidone | Methdilazine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1664,
24,
104
]
],
[
[
1664,
63,
13
],
[
13,
24,
104
]
],
[
[
1664,
24,
820
],
[
820,
1,
104
]
],
[
[
1664,
24,
537
],
[
537,
40... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazi... |
DB00685 | DB00987 | 1,299 | 1,224 | [
"DDInter1887",
"DDInter460"
] | Trovafloxacin | Cytarabine | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Minor | 0 | [
[
[
1299,
23,
1224
]
],
[
[
1299,
6,
3199
],
[
3199,
57,
1224
]
],
[
[
1299,
1,
872
],
[
872,
62,
1224
]
],
[
[
1299,
1,
739
],
[
739,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (C... | Trovafloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Cytarabine (Compound)
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Trovafloxacin (Compound) resembles Lomefloxacin (Com... |
DB00014 | DB00377 | 521 | 1,494 | [
"DDInter839",
"DDInter1382"
] | Goserelin | Palonosetron | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Moderate | 1 | [
[
[
521,
24,
1494
]
],
[
[
521,
21,
28723
],
[
28723,
60,
1494
]
],
[
[
521,
23,
112
],
[
112,
62,
1494
]
],
[
[
521,
24,
495
],
[
495,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Malnutrition"
],
[
"Malnutrition",
"{u} (Side Effect) i... | Goserelin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Palonosetron (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with... |
DB00938 | DB06335 | 455 | 761 | [
"DDInter1635",
"DDInter1646"
] | Salmeterol | Saxagliptin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
455,
24,
761
]
],
[
[
455,
6,
7524
],
[
7524,
45,
761
]
],
[
[
455,
21,
28966
],
[
28966,
60,
761
]
],
[
[
455,
63,
307
],
[
307,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Salmeterol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Salmeterol (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Salmeterol may cause a moderate interaction that could exace... |
DB00023 | DB00620 | 305 | 175 | [
"DDInter127",
"DDInter1855"
] | Asparaginase Escherichia coli | Triamcinolone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
305,
24,
175
]
],
[
[
305,
24,
1573
],
[
1573,
1,
175
]
],
[
[
305,
24,
155
],
[
155,
63,
175
]
],
[
[
305,
24,
617
],
[
617,
40... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxyme... |
DB09065 | DB11757 | 760 | 960 | [
"DDInter424",
"DDInter994"
] | Cobicistat | Istradefylline | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Major | 2 | [
[
[
760,
25,
960
]
],
[
[
760,
64,
1135
],
[
1135,
23,
960
]
],
[
[
760,
24,
1499
],
[
1499,
24,
960
]
],
[
[
760,
64,
134
],
[
134,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may caus... |
DB00013 | DB01242 | 1,255 | 1,237 | [
"DDInter1905",
"DDInter410"
] | Urokinase | Clomipramine | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1255,
24,
1237
]
],
[
[
1255,
64,
1578
],
[
1578,
24,
1237
]
],
[
[
1255,
24,
1274
],
[
1274,
24,
1237
]
],
[
[
1255,
25,
498
],
[
498... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",... | Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may caus... |
DB00295 | DB01324 | 475 | 178 | [
"DDInter1244",
"DDInter1490"
] | Morphine | Polythiazide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
475,
24,
178
]
],
[
[
475,
24,
504
],
[
504,
40,
178
]
],
[
[
475,
21,
28835
],
[
28835,
60,
178
]
],
[
[
475,
24,
85
],
[
85,
2... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Polythiazide (Compound)
Morphine (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Polythiazide (Compound)
Morphine may cau... |
DB00618 | DB13749 | 1,572 | 1,473 | [
"DDInter498",
"DDInter1116"
] | Demeclocycline | Magnesium gluconate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
1572,
24,
1473
]
],
[
[
1572,
24,
544
],
[
544,
24,
1473
]
],
[
[
1572,
40,
964
],
[
964,
24,
1473
]
],
[
[
1572,
1,
1545
],
[
1545,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium ... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause ... |
DB00845 | DB00927 | 1,490 | 1,559 | [
"DDInter406",
"DDInter712"
] | Clofazimine | Famotidine | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1490,
24,
1559
]
],
[
[
1490,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1490,
24,
286
],
[
286,
62,
1559
]
],
[
[
1490,
23,
112
],
[
112... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Clofazimine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caus... | Clofazimine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when ta... |
DB06176 | DB10276 | 1,342 | 1,624 | [
"DDInter1616",
"DDInter1623"
] | Romidepsin | Rotavirus vaccine | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1342,
25,
1624
]
],
[
[
1342,
63,
770
],
[
770,
25,
1624
]
],
[
[
1342,
25,
375
],
[
375,
25,
1624
]
],
[
[
1342,
64,
478
],
[
478,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Th... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Romidepsin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol ... |
DB01191 | DB09043 | 1,039 | 135 | [
"DDInter518",
"DDInter36"
] | Dexfenfluramine | Albiglutide | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1039,
24,
135
]
],
[
[
1039,
63,
126
],
[
126,
23,
135
]
],
[
[
1039,
63,
176
],
[
176,
24,
135
]
],
[
[
1039,
25,
341
],
[
341,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine... |
DB08875 | DB11853 | 1,618 | 230 | [
"DDInter262",
"DDInter1577"
] | Cabozantinib | Relugolix | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
1618,
25,
230
]
],
[
[
1618,
25,
129
],
[
129,
23,
230
]
],
[
[
1618,
24,
1094
],
[
1094,
23,
230
]
],
[
[
1618,
62,
112
],
[
112,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Cabozantinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may... |
DB03619 | DB06810 | 557 | 397 | [
"DDInter501",
"DDInter1484"
] | Deoxycholic acid | Plicamycin | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
557,
24,
397
]
],
[
[
557,
63,
885
],
[
885,
24,
397
]
],
[
[
557,
24,
578
],
[
578,
63,
397
]
],
[
[
557,
63,
1172
],
[
1172,
2... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Ticag... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.